PBYI
Income statement / Annual
Last year (2024), Puma Biotechnology, Inc.'s total revenue was $230.47 M,
a decrease of 2.19% from the previous year.
In 2024, Puma Biotechnology, Inc.'s net income was $30.28 M.
See Puma Biotechnology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$230.47 M |
$235.64 M |
$228.00 M |
$253.20 M |
$225.10 M |
$272.30 M |
$251.00 M |
$27.70 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$64.40 M
|
$62.68 M
|
$55.10 M
|
$63.70 M
|
$39.40 M
|
$36.80 M
|
$34.60 M
|
$5.60 M
|
$1.15 M
|
$776,000.00
|
| Gross Profit |
$166.06 M
|
$172.96 M
|
$172.90 M
|
$189.50 M
|
$185.70 M
|
$235.50 M
|
$216.40 M
|
$22.10 M
|
-$1.15 M
|
-$776,000.00
|
| Gross Profit Ratio |
0.72
|
0.73
|
0.76
|
0.75
|
0.82
|
0.86
|
0.86
|
0.8
|
0
|
0
|
| Research and Development Expenses |
$54.94 M
|
$50.38 M
|
$52.20 M
|
$71.90 M
|
$97.70 M
|
$132.90 M
|
$164.90 M
|
$207.80 M
|
$222.80 M
|
$208.50 M
|
| General & Administrative Expenses |
$80.68 M
|
$88.43 M
|
$89.98 M
|
$116.29 M
|
$118.49 M
|
$140.51 M
|
$146.19 M
|
$106.70 M
|
$53.80 M
|
$31.80 M
|
| Selling & Marketing Expenses |
-$519,000.00
|
$881,000.00
|
$22,000.00
|
$6,000.00
|
-$88,000.00
|
$1.19 M
|
$12,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$80.16 M
|
$89.31 M
|
$90.00 M
|
$116.30 M
|
$118.40 M
|
$141.70 M
|
$146.20 M
|
$106.70 M
|
$53.80 M
|
$31.80 M
|
| Other Expenses |
$0.00
|
$625,000.00
|
-$28,000.00
|
$300,000.00
|
$400,000.00
|
$200,000.00
|
-$9.70 M
|
-$100,000.00
|
-$400,000.00
|
$25,000.00
|
| Operating Expenses |
$135.10 M
|
$140.32 M
|
$142.20 M
|
$188.20 M
|
$216.10 M
|
$274.60 M
|
$311.10 M
|
$314.50 M
|
$276.60 M
|
$240.30 M
|
| Cost And Expenses |
$199.50 M
|
$203.00 M
|
$197.30 M
|
$251.90 M
|
$255.50 M
|
$311.40 M
|
$345.70 M
|
$320.10 M
|
$276.60 M
|
$240.30 M
|
| Interest Income |
$4.72 M
|
$2.61 M
|
$800,000.00
|
$100,000.00
|
$500,000.00
|
$2.80 M
|
$1.80 M
|
$1.20 M
|
$1.00 M
|
$1.00 M
|
| Interest Expense |
$12.45 M
|
$13.33 M
|
$11.50 M
|
$12.80 M
|
$14.10 M
|
$15.00 M
|
$11.00 M
|
$700,000.00
|
$958,000.00
|
$971,000.00
|
| Depreciation & Amortization |
$11.52 M
|
$11.52 M
|
$8.92 M
|
$10.60 M
|
$7.20 M
|
$4.80 M
|
$7.38 M
|
$2.81 M
|
$1.15 M
|
$776,000.00
|
| EBITDA |
$48.08 M |
$47.52 M |
$20.97 M |
-$5.40 M |
-$38.54 M |
-$55.72 M |
-$95.21 M |
-$288.42 M |
-$275.45 M |
-$239.50 M |
| EBITDA Ratio |
0.21
|
0.2
|
0.14
|
0.01
|
-0.13
|
-0.13
|
-0.41
|
-10.52
|
0
|
0
|
| Operating Income Ratio |
0.13
|
0.14
|
0.1
|
-0.04
|
-0.14
|
-0.14
|
-0.38
|
-10.56
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.87 M
|
-$9.97 M
|
-$23.26 M
|
-$30.09 M
|
-$29.39 M
|
$53,000.00
|
-$18.92 M
|
$435,000.00
|
$585,000.00
|
$996,000.00
|
| Income Before Tax |
$24.10 M
|
$22.67 M
|
$500,000.00
|
-$28.80 M
|
-$59.80 M
|
-$75.60 M
|
-$113.60 M
|
-$292.00 M
|
-$276.00 M
|
-$239.30 M
|
| Income Before Tax Ratio |
0.1
|
0.1
|
0
|
-0.11
|
-0.27
|
-0.28
|
-0.45
|
-10.54
|
0
|
0
|
| Income Tax Expense |
-$6.18 M
|
$1.08 M
|
$500,000.00
|
$300,000.00
|
$200,000.00
|
$7.12 M
|
-$7.92 M
|
-$2.21 M
|
-$2.15 M
|
-$1.75 M
|
| Net Income |
$30.28 M
|
$21.59 M
|
$912,000.00
|
-$29.10 M
|
-$60.00 M
|
-$82.72 M
|
-$113.60 M
|
-$292.00 M
|
-$276.00 M
|
-$239.30 M
|
| Net Income Ratio |
0.13
|
0.09
|
0
|
-0.11
|
-0.27
|
-0.3
|
-0.45
|
-10.54
|
0
|
0
|
| EPS |
0.62 |
0.46 |
0.0204 |
-0.72 |
-1.52 |
-2.13 |
-2.99 |
-7.86 |
-8.29 |
-7.45 |
| EPS Diluted |
0.62 |
0.45 |
0.0203 |
-0.72 |
-1.52 |
-2.13 |
-2.99 |
-7.86 |
-8.29 |
-7.45 |
| Weighted Average Shares Out |
$48.65 M
|
$47.13 M
|
$44.67 M
|
$40.64 M
|
$39.58 M
|
$38.77 M
|
$37.94 M
|
$37.17 M
|
$33.30 M
|
$32.13 M
|
| Weighted Average Shares Out Diluted |
$49.10 M
|
$47.55 M
|
$44.93 M
|
$40.64 M
|
$39.58 M
|
$38.77 M
|
$37.94 M
|
$37.17 M
|
$33.30 M
|
$32.13 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
